The impact of HB 670 on state law is notable as it would repeal prior provisions ensuring drug benefits for retirees under certain conditions. The shift is expected to lead to cost savings for the state by reducing its financial obligations towards retiree healthcare. However, it will place a greater reliance on federal Medicare plans, potentially complicating access to drug benefits for many affected retirees. Advocates highlight the necessity of maintaining quality healthcare coverage for retirees, pushing back against the bill, fearing that it could jeopardize their well-being due to discontinuation of state support.
Summary
House Bill 670 proposes significant changes to prescription drug benefits for state retirees, particularly those who are Medicare-eligible. The bill aims to eliminate existing state-funded prescription drug benefits for retirees who began state service on or after July 1, 2011, along with their spouses and dependent children. Instead, it seeks to streamline the system by repealing specific programs such as the Maryland State Retiree Prescription Drug Coverage Program and creating a new framework for Medicare-eligible individuals to ensure their drug coverage aligns with federal programs. This act aims to clarify responsibilities and eligibility for coverage, ensuring that retirees understand their options as they transition to different benefits under federal law.
Contention
Significant contention arises around the perceived fairness of stripping prescription drug benefits from future retirees while continuing to provide them to those who retired earlier. Opponents argue that this legislation undermines the promises made to state employees about their benefits. They express concern that the bill could create disparities among retirees based on their start date with the state, potentially leading to inequities in healthcare access. Moreover, there are worries about how effectively the new programs will operate and manage reimbursements for retirees compared to the previously existing programs.
Directing The State Employee Benefits Committee And The Secretary Of Human Resources To Engage With Independent Consultants And Other Supply Chain Tactics For Cost Containment Of Prescription Drugs For State Employees And Retirees Insurance Programs.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.